These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16056003)

  • 1. Common methodological flaws in economic evaluations.
    Drummond M; Sculpher M
    Med Care; 2005 Jul; 43(7 Suppl):5-14. PubMed ID: 16056003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities.
    Hoffmann C; Stoykova BA; Nixon J; Glanville JM; Misso K; Drummond MF
    Value Health; 2002; 5(2):71-8. PubMed ID: 11918822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of systematic reviews of economic evaluations in health care.
    Jefferson T; Demicheli V; Vale L
    JAMA; 2002 Jun; 287(21):2809-12. PubMed ID: 12038919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological reviews of economic evaluations in health care: what do they target?
    Hutter MF; Rodríguez-Ibeas R; Antonanzas F
    Eur J Health Econ; 2014 Nov; 15(8):829-40. PubMed ID: 23974963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluations and randomized trials in spinal disorders: principles and methods.
    Korthals-de Bos I; van Tulder M; van Dieten H; Bouter L
    Spine (Phila Pa 1976); 2004 Feb; 29(4):442-8. PubMed ID: 15094541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
    Franken M; Koopmanschap M; Steenhoek A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation.
    Drummond MF; Aguiar-Ibanez R; Nixon J
    Singapore Med J; 2006 Jun; 47(6):456-61; quiz 462. PubMed ID: 16752012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytic considerations in economic evaluations of multinational cardiovascular clinical trials.
    Torti FM; Reed SD; Schulman KA
    Value Health; 2006; 9(5):281-91. PubMed ID: 16961546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating economic evaluations into decision-making: the Ontario experience.
    Laupacis A
    Med Care; 2005 Jul; 43(7 Suppl):15-9. PubMed ID: 16056004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Interaction between Price Negotiations and Heterogeneity: Implications for Economic Evaluations.
    O'Donnell H; McCullagh L; Barry M; Walsh C
    Med Decis Making; 2020 Feb; 40(2):144-155. PubMed ID: 32009545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of economic evaluations of vaccination programs in mainland China: Are they sufficient to inform decision making?
    Pan XF; Griffiths UK; Pennington M; Yu H; Jit M
    Vaccine; 2015 Nov; 33(46):6164-72. PubMed ID: 26435189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making economic evaluations more helpful for treatment choices in haemophilia.
    Drummond M; Houwing N; Slothuus U; Giangrande P
    Haemophilia; 2017 Mar; 23(2):e58-e66. PubMed ID: 28111847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees.
    Anell A
    Eur J Health Econ; 2004 Feb; 5(1):28-35. PubMed ID: 15452762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value for money in the health sector: the contribution of primary health care.
    Mills A; Drummond M
    Health Policy Plan; 1987 Jun; 2(2):107-28. PubMed ID: 10312103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of health promotion for older people-methodological problems and challenges.
    Huter K; Kocot E; Kissimova-Skarbek K; Dubas-Jakóbczyk K; Rothgang H
    BMC Health Serv Res; 2016 Sep; 16 Suppl 5(Suppl 5):328. PubMed ID: 27609155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.